(Q33230717)

24 July 2017

1 reference

title

Psychotropic drugs induced weight gain: a review of the literature concerning epidemiological data, mechanisms and management (English)

1 reference

24 July 2017

1 reference

Ruetsch O

1

1 reference

24 July 2017

Viala A

2

1 reference

24 July 2017

Bardou H

3

1 reference

24 July 2017

Martin P

4

1 reference

24 July 2017

Vacheron MN

5

1 reference

24 July 2017

1 July 2005

1 reference

L'Encephale: revue de psychiatrie clinique biologique et therapeutique

24 July 2017

10

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

24 July 2017

31

1 reference

24 July 2017

4 Pt 1

1 reference

24 July 2017

507-516

1 reference

Weight gain in first-episode psychosis

24 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982412-1

Consensus development conference on antipsychotic drugs and obesity and diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982412-1

Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982412-1

A program for treating olanzapine-related weight gain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982412-1

Lithium maintenance treatment of manic-melancholic patients: its role in the daily routine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982412-1

Weight gain. A side-effect of tricyclic antidepressants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982412-1

A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982412-1

Weight gain associated with psychotropic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982412-1

Serum leptin levels increase rapidly after initiation of clozapine therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982412-1

A Double-Blind, Placebo-Controlled, Prophylaxis Study of Lamotrigine in Rapid-Cycling Bipolar Disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982412-1

The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982412-1

Atypical antipsychotics and new onset diabetes mellitus. An overview of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982412-1

Association of olanzapine-induced weight gain with an increase in body fat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982412-1

Differential activation of orexin neurons by antipsychotic drugs associated with weight gain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982412-1

Resting metabolic rate is reduced in patients treated with antidepressants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982412-1

Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982412-1

Excess mortality of mental disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982412-1

Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982412-1

Effects of antidepressants on weight and on the plasma levels of leptin, TNF-alpha and soluble TNF receptors: A longitudinal study in patients treated with amitriptyline or paroxetine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982412-1

Bipolar disorder, obesity, and pharmacotherapy-associated weight gain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982412-1

Six-month review of weight and metabolic parameters in patients receiving clozapine, risperidone, olanzapine, or quetiapine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982412-1

Body weight, the tumor necrosis factor system, and leptin production during treatment with mirtazapine or venlafaxine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982412-1

Metabolic consequences of atypical antipsychotic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982412-1

Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982412-1

The Effects of an Educational Intervention on Antipsychotic‐Induced Weight Gain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982412-1

Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982412-1

Correlates of overweight and obesity in 644 patients with bipolar disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982412-1

Antipsychotic-induced weight gain: bipolar disorder and leptin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982412-1

Pronounced early increase in circulating leptin predicts a lower weight gain during clozapine treatment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982412-1

Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982412-1

Serum insulin and leptin levels in valproate-associated obesity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982412-1

The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982412-1

Bodyweight gain associated with atypical antipsychotics: epidemiology and therapeutic implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982412-1

Atypical antipsychotics and weight gain--a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982412-1

Clozapine and weight gain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982412-1

Phenothiazines and Diabetes in Hospitalized Women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982412-1

Cognitive behavior therapy for weight gain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982412-1

A program for managing weight gain associated with atypical antipsychotics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982412-1

Lithium treatment and weight gain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982412-1

Serum leptin changes in epileptic patients who gain weight after therapy with valproic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982412-1

Obesity as a risk factor for antipsychotic noncompliance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982412-1

Bodyweight gain with atypical antipsychotics. A comparative review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982412-1

The effects of novel antipsychotics on glucose and lipid levels.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982412-1

Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982412-1

Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982412-1

Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982412-1

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0013-7006(05)82412-1

1 reference

24 July 2017

1 reference